Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV

Inclusion Criteria: * 18-65 years old (including 18 and 65 years old); * Chronic HBV infection confirmed by serological, etiological and clinical diagnosis (HBsAg positive for more than 6 months); * HBV-DNA negative after nucleoside (acid) treatment; * Laboratory test values meet the following requirements : * Liver function : AST, ALT ≤ 3×ULN; serum total bilirubin≤2×ULN; direct bilirubin≤1.5×ULN; serum albumin≥35 g/L (blood collection is not within 2 weeks before transfusion of albumin); * Hematology: white blood cell count\>3.0×109/L, ANC\>1.5×109/L; platelet\>1×ULN; hemoglobin 120g/L. (No blood transfusion (including transfusion of red blood cells and platelets) and EPO, TPO, leukocyte-stimulating factor were required within 2 weeks before blood collection) ; * Renal function: serum creatinine≤1×ULN; * Thyroid function: TSH and T4 in normal range or thyroid function can be completely controlled ; * Determination of serum immunoglobulin : IgM≤ULN; * Coagulation function: International normalized ratio: INR≤1×ULN; Exclusion Criteria: * Chronic HBV with unexplained portal hypertension; * Subjects with liver cancer or serum AFP \>1×ULN; * Previously received FXR therapy;